These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31778662)

  • 1. Globotriaosylceramide-induced reduction of K
    Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
    Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated interleukin-8 expression by skin fibroblasts as a potential contributor to pain in women with Fabry disease.
    Hofmann L; Grüner J; Klug K; Breyer M; Klein T; Hochheimer V; Wagenhäuser L; Wischmeyer E; Üçeyler N
    PLoS One; 2024; 19(4):e0300687. PubMed ID: 38593151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-α links heat and inflammation with Fabry pain.
    Üçeyler N; Urlaub D; Mayer C; Uehlein S; Held M; Sommer C
    Mol Genet Metab; 2019 Jul; 127(3):200-206. PubMed ID: 31221509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.
    Üçeyler N; Schröter N; Kafke W; Kramer D; Wanner C; Weidemann F; Sommer C
    PLoS One; 2016; 11(11):e0166484. PubMed ID: 27851774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
    Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
    PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
    Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
    Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy.
    Liguori R; Incensi A; de Pasqua S; Mignani R; Fileccia E; Santostefano M; Biagini E; Rapezzi C; Palmieri S; Romani I; Borsini W; Burlina A; Bombardi R; Caprini M; Avoni P; Donadio V
    PLoS One; 2017; 12(7):e0180581. PubMed ID: 28672034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different expression of β subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes.
    Pethő Z; Tanner MR; Tajhya RB; Huq R; Laragione T; Panyi G; Gulko PS; Beeton C
    Arthritis Res Ther; 2016 May; 18(1):103. PubMed ID: 27165430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of small fiber pathology in a mouse model of Fabry disease.
    Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
    Elife; 2018 Oct; 7():. PubMed ID: 30328411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
    Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
    Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: A family study.
    Cerón-Rodríguez M; Ramón-García G; Barajas-Colón E; Franco-Álvarez I; Salgado-Loza JL
    Mol Genet Genomic Med; 2019 Nov; 7(11):e981. PubMed ID: 31566927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
    Lee MH; Choi EN; Jeon YJ; Jung SC
    Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered globotriaosylceramide accumulation and mucosal neuronal fiber density in the colon of the Fabry disease mouse model.
    Masotti M; Delprete C; Dothel G; Donadio V; Rimondini R; Politei JM; Liguori R; Caprini M
    Neurogastroenterol Motil; 2019 Mar; 31(3):e13529. PubMed ID: 30609268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyso-Gb3 activates Notch1 in human podocytes.
    Sanchez-Niño MD; Carpio D; Sanz AB; Ruiz-Ortega M; Mezzano S; Ortiz A
    Hum Mol Genet; 2015 Oct; 24(20):5720-32. PubMed ID: 26206887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
    Biancini GB; Vanzin CS; Rodrigues DB; Deon M; Ribas GS; Barschak AG; Manfredini V; Netto CB; Jardim LB; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2012 Feb; 1822(2):226-32. PubMed ID: 22085605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA.
    Higuchi T; Shimada Y; Takahashi Y; Kato F; Ohashi T; Kobayashi H
    Mol Genet Metab; 2024; 143(1-2):108545. PubMed ID: 39068683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
    Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T
    Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.